Hospital OR staffing evolves with predictive analytics and cross-training to optimize surgical care amid workforce shortages and burnout.
Proceeds support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells (“Tregs”) in inflammatory diseases affecting skin and other ...
Proceeds will support advancement of the Company's oral small molecule GLP-1 candidate and other novel cardiometabolic programs into clinical development BOULDER, Colo., March 31, 2026 /PRNewswire/ -- ...
The company expects to file applications to begin human testing for several of the new programs within the next 12 to 24 ...